Story
Teleflex Stock Rallies After BofA Securities Upgrade to 'Buy'
Summary
Shares of medical device maker Teleflex Inc. gained more than 4% in a down market after BofA Securities upgraded the stock, citing confidence in new management and easing business headwinds.
Shares of Teleflex Inc. (NYSE: TFX) rose sharply against a broader market decline, gaining 4.6% in afternoon trading after a bullish analyst upgrade. The move was driven by BofA Securities, which raised its rating on the medical device company to 'Buy' from 'Neutral'.
BofA Cites Turnaround Potential
In a note to clients, BofA Securities raised its price target on Teleflex to $158 from a previous $145. The bank's analysts framed the company as a potential "re-rating story" under its new management team.
BofA's thesis rests on the view that significant execution risks are becoming more manageable. These challenges, which have previously weighed on the stock, include:
- Integration difficulties within its Interventional business unit.
- Uncertainty surrounding moves related to its partner, Biotronik.
The firm believes these headwinds are now increasingly reflected in the stock's current valuation. BofA projects that 2027 will be the first "clean" year for the company, free from major integration issues, allowing its underlying growth to become more apparent.
Earnings Outlook and Valuation
AdBofA also pointed to a positive earnings outlook, projecting fiscal 2027 earnings per share (EPS) of $11.25. This forecast is above the current Wall Street consensus of $10.98. The bank's new $158 price target is based on a valuation of 14 times that 2027 EPS estimate.
Analysts also noted a potential near-term catalyst, suggesting a tariff refund could provide an upside to EPS in the third quarter of 2026. The positive sentiment from BofA follows a separate upgrade earlier in the week from Zacks Research, which raised its rating on Teleflex to 'Strong-Buy'.
Defying a Weaker Market
The rally in Teleflex shares was entirely company-specific, standing in stark contrast to the day's market trend. Major indices were in negative territory, with the S&P 500, Dow Jones, and Nasdaq all declining by more than 0.6% during the session.
Furthermore, there was no material news from key competitors like Boston Scientific or Zimmer Biomet that would have provided a sector-wide lift. This underscores the BofA upgrade as the primary driver behind the stock's outperformance, which saw shares reach a session high of $128.62.
Read next
More on Stocks
Cleveland-Cliffs Stock Falls as Subsidiary Idles Plant Citing US Tariffs
Shares of Cleveland-Cliffs dropped nearly 8% following a report that its Canadian unit, Stelco, will halt operations at a key processing facility due to pressures from U.S. import tariffs. The company plans to consolidate production at another plant to maintain overall output.
AMD to Acquire AI Startup World Labs for $8.2 Billion in All-Stock Deal
Advanced Micro Devices announced an $8.2 billion all-stock deal to buy spatial intelligence startup World Labs, a strategic move to challenge Nvidia's leadership in next-generation AI for robotics and simulation.
Pfizer, BioNTech, Moderna Lose Bid to Dismiss Bayer's mRNA Patent Lawsuit
A U.S. federal judge has denied a request from major COVID-19 vaccine makers to dismiss a patent infringement lawsuit filed by Bayer AG. The case, which will now proceed, centers on messenger RNA technology Bayer's Monsanto unit claims it developed.
AAR to Acquire $1.8 Billion Controlling Stake in MRO Holdings, WSJ Reports
Aviation services provider AAR Corp. has reportedly agreed to buy a 65% stake in aircraft maintenance firm MRO Holdings for $1.8 billion, a move aimed at expanding its service capacity and boosting profit margins.